Systemic Psoriasis Therapeutics Industry 2020 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Systemic Psoriasis Therapeutics Industry 2020

Description:

The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. – PowerPoint PPT presentation

Number of Views:161

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Systemic Psoriasis Therapeutics Industry 2020


1
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive
Growth by GBI Research
  • Explore all reports for Dermatology therapeutic
    market
  • _at_
  • http//www.rnrmarketresearch.com/reports/life-scie
    nces/pharmaceuticals/therapeutics/dermatology-ther
    apeutics

2
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  • The collection of Dermatology therapeutic
    market research reports has a new addition of
    Systemic Psoriasis Therapeutics in Major
    Developed Markets to 2020 Continued Uptake of
    Biologics and Novel Pipeline Drugs to Drive
    Growth on RnRMarketResearch.com. GBI Research
    has released its pharma report Systemic
    Psoriasis Therapeutics in Major Developed Markets
    to 2020 Continued Uptake of Biologics and Novel
    Pipeline Drugs to Drive Growth. The systemic
    psoriasis market is forecast to grow
    substantially over the forecast period from 5.0
    billion in 2013 to 10.4 billion in 2020, across
    the eight major markets. This growth will be
    driven by a rising treatment population and the
    continued uptake of biologics.
  • Biologics will continue to drive market growth
    despite leading brands Enbrel (etanercept),
    Humira (adalimumab) and Remicade (infliximab)
    losing patent protection in most of the major
    markets over the forecast period.
  • Request sample copy of this report _at_
    http//www.rnrmarketresearch.com/contacts/request-
    sample?rname148417 .

3
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  • Although the market will suffer revenue losses as
    a result of sales erosion from biosimilar
    competitors, this will be offset by the emergence
    of novel therapies. Most notably, these include
    monoclonal antibodies secukinumab, ixekizumab and
    brodalumab, which are currently being developed
    by Alcon (Novartis subsidiary), Eli Lilly and
    Amgen, respectively.
  • Scope
  • An introduction to psoriasis, which includes
    symptoms, epidemiology, etiology,
    pathophysiology, diagnosis and treatment
  • Analysis of the major systemic therapies in the
    current psoriasis marketed landscape
  • Analysis of the pipeline for psoriasis, which
    includes a breakdown of pipeline molecules by
    phase of development, molecule type, molecular
    target and novelty.
  • Complete Report is available _at_ http//www.rnrmarke
    tresearch.com/systemic-psoriasis-therapeutics-in-m
    ajor-developed-markets-to-2020-continued-uptake-of
    -biologics-and-novel-pipeline-drugs-to-drive-growt
    h-market-report.html

4
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  •  Forecast projections for the systemic psoriasis
    market to 2020. Analysis is provided for the
    global market and each of the eight major
    markets. The forecast incorporates projected, low
    and high variance scenarios based on treatment
    usage patterns and annual therapy costs in each
    of the major markets.
  • Analysis of strategic consolidations, including
    co-development and licensing deals, within the
    psoriasis indication
  • Reasons to buy
  • Understand the current systemic psoriasis
    marketed products landscape and recognize the
    dominant therapeutic agents and pharmaceutical
    players involved
  • Identify trends and developments within the
    psoriasis pipeline and consider how the future
    competitive environment will be impacted
  • Request sample copy of this report _at_
    http//www.rnrmarketresearch.com/contacts/request-
    sample?rname148417 .

5
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  • Consider market opportunities and potential risks
    by examining the psoriasis clinical trial
    landscape in relation to industry averages
  • Observe projections for treatment usage patterns,
    annual therapy costs and market growth in the
    eight major markets and understand reasons for
    variance in projected patterns of growth in the
    eight major markets
  • Table of Contents
  • 1 Table of Contents 4 1.1 List of Tables 6 1.2
    List of Figures 7
  • 2 Introduction 8 2.1 Overview 8 2.2 Epidemiology
    9 2.3 Etiology, Co-morbidities and Risk Factors
    10 2.3.1 Genetics 10 2.3.2 Psoriatic Arthritis 10
  • Complete Report is available _at_ http//www.rnrmarke
    tresearch.com/systemic-psoriasis-therapeutics-in-m
    ajor-developed-markets-to-2020-continued-uptake-of
    -biologics-and-novel-pipeline-drugs-to-drive-growt
    h-market-report.html

6
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  • 2.3.3 Mental Health Disorders 11 2.3.4 Metabolic
    Syndrome, Smoking, Diet and Alcohol Consumption
    11 2.3.5 Infections 11 2.3.6 Köebner Phenomenon
    12 2.3.7 Other Immune-mediated Diseases 12 2.4
    Pathophysiology 12 2.5 Diagnosis 13 2.6 Treatment
    Options 13 2.6.1 Pharmacological Therapies
    14 2.6.2 Non-pharmacological Therapies 15 2.6.3
    Combination and Rotational Therapies 15 2.6.4
    Quality of Life Assessments 16 2.7 Summary 16
  • Request sample copy of this report _at_
    http//www.rnrmarketresearch.com/contacts/request-
    sample?rname148417 .

7
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  • 3 Marketed Products 17 3.1 Overview 17 3.2
    Methotrexate-based Products 17 3.3
    Sandimmune/Neoral (cyclosporine/modified
    cyclosporine) - Novartis 18 3.4 Soriatane
    (acitretin) - Steifel Laboratories 19 3.5
    Fumaderm (dimethyl fumarate and ethyl fumarate) -
    Biogen Idec 20 3.6 Humira (adalimumab) - Abbvie
    Inc. 21 3.7 Enbrel (etanercept) - Amgen Inc.
    22 3.8 Remicade (infliximab) - Janssen Biotech
    23 3.9 Stelara (ustekinumab) - Janssen Biotech
    24 3.10 Marketed Products Heat Map 25
  • 4 Pipeline 28 4.1 Overview 28
  • Complete Report is available _at_
    http//www.rnrmarketresearch.com/systemic-psoriasi
    s-therapeutics-in-major-developed-markets-to-2020-
    continued-uptake-of-biologics-and-novel-pipeline-d
    rugs-to-drive-growth-market-report.html

8
Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
  • For more details contact Mr. Priyank Tiwari
    sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.
About PowerShow.com